Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359254 · ClinicalTrials.gov registry record · Phase 2
Cord Blood Transplantation for Patients With Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01359254: Clinical Trial Phase 2 study, sponsored by University of Chicago.
NCT01359254 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01359254, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.
Primary Outcome
Percent of subjects with cord blood engraftment on or before day 100. Detectable cord blood engraftment should be present by day 100 in at least 50% of patients. As of 44 days post-transplant, only haploidentical donor chimerism achieved in the one patient enrolled in the Fludarabine, melphalan, and ATG arm. There were no cord cells detected for this patient.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Busulfan
- DRUG Total Body Irradiation (TBI)
- DRUG Antithymocyte Globulin (ATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Why NCT01359254 stopped before completion
NCT01359254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01359254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01359254 about?
NCT01359254 is a clinical study titled "Cord Blood Transplantation for Patients With Cancer". The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.
What is the current status of trial NCT01359254?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2010-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01359254?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Busulfan (DRUG), Total Body Irradiation (TBI) (DRUG), Antithymocyte Globulin (ATG) (DRUG).
Who is sponsoring clinical trial NCT01359254?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01359254's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia